🔎 Trials Near Me

Beranda › Kanker Kolon › Colorado

Uji klinis Kanker Kolon di Colorado

19 studi untuk Kanker Kolon mencari peserta di lokasi di Colorado.

Kota di Colorado

Teks studi resmi (Bahasa Inggris)

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

  • Penrose-Saint Francis Healthcare, Colorado Springs
  • Rocky Mountain Cancer Centers-Penrose, Colorado Springs
  • Saint Francis Cancer Center, Colorado Springs
  • dan 6 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07283939

Family Communications After Genetic Testing

  • Penrose-Saint Francis Healthcare, Colorado Springs
  • Rocky Mountain Cancer Centers-Penrose, Colorado Springs
  • Saint Francis Cancer Center, Colorado Springs
  • dan 6 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07143487

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  • University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0087), Fort Collins
  • Rocky Mountain Cancer Centers (RMCC) ( Site 8000), Lone Tree
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06997497

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  • Rocky Mountain Cancer Centers, LLP, Aurora
  • Rocky Mountain Cancer Centers - Boulder, Boulder
  • Rocky Mountain Cancer Centers, LLP, Centennial
  • dan 18 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • University of Colorado Cancer Center, Aurora
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

  • SCRI at HCA HealthONE, Denver
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07705334

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

  • GSK Investigational Site, Aurora
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07213609

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  • Sarah Cannon Research Institute Scri Oncology Partners, Aurora
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07284849

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • University of Colorado, Aurora
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

  • Rocky Mountain Regional VA Medical Center, Aurora
  • UCHealth University of Colorado Hospital, Aurora
  • Penrose-Saint Francis Healthcare, Colorado Springs
  • dan 11 lainnya
Menerima peserta
Usia 45 hingga 70 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05080673

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  • UCHealth University of Colorado Hospital, Aurora
  • Intermountain Health Platte Valley Hospital, Brighton
  • Penrose-Saint Francis Healthcare, Colorado Springs
  • dan 26 lainnya
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05174169

Integrated Cancer Repository for Cancer Research

  • Advent Health, Greenwood Village
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

  • Sarah Cannon, SCRI Oncology Partners - Health One, Denver
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT04678648

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

  • Rocky Mountain Cancer Center - Primary, Denver
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT07011576

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

  • Sarah Cannon Research Institute, Denver
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06239194

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

  • Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital, Denver
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 49 · Semua jenis kelamin · Diperbarui 24 Apr 2026 · NCT05732623

Survivors Uniting for Remote Guided Exercise

  • Human Performance Clinical Research Lab, Fort Collins
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Mar 2026 · NCT07290309

Improving Care for Rural Patients With Solid Tumors

  • University of Colorado Hospital, Aurora
  • Memorial Hospital Central, Colorado Springs
  • Memorial Hospital North, Colorado Springs
  • dan 10 lainnya
Menerima peserta
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT04916990

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Aurora
  • Massive Bio SYNERGY-AI site, Denver
  • Massive Bio SYNERGY-AI site, Littleton
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.